Logo image of MREO

MEREO BIOPHARMA GROUP PL-ADR (MREO) Stock Overview

USA - NASDAQ:MREO - US5894921072 - ADR

1.85 USD
+0.11 (+6.32%)
Last: 9/22/2025, 8:47:01 PM
1.8499 USD
0 (-0.01%)
After Hours: 9/22/2025, 8:47:01 PM

MREO Key Statistics, Chart & Performance

Key Statistics
52 Week High4.72
52 Week Low1.47
Market Cap294.15M
Shares159.00M
Float29.64M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.35
PEN/A
Fwd PEN/A
Earnings (Next)11-10 2025-11-10
IPO06-09 2016-06-09
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


MREO short term performance overview.The bars show the price performance of MREO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30

MREO long term performance overview.The bars show the price performance of MREO in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 50 -50 100

The current stock price of MREO is 1.85 USD. In the past month the price increased by 8.82%. In the past year, price decreased by -55.31%.

MEREO BIOPHARMA GROUP PL-ADR / MREO Daily stock chart

MREO Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.02 393.22B
AMGN AMGEN INC 13.11 153.97B
GILD GILEAD SCIENCES INC 14.53 139.58B
VRTX VERTEX PHARMACEUTICALS INC 22.62 98.23B
REGN REGENERON PHARMACEUTICALS 13.05 63.14B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 60.16B
ARGX ARGENX SE - ADR 79.83 45.29B
ONC BEONE MEDICINES LTD-ADR 5.9 40.16B
INSM INSMED INC N/A 30.65B
NTRA NATERA INC N/A 24.59B
BNTX BIONTECH SE-ADR N/A 23.73B
BIIB BIOGEN INC 8.79 20.62B

About MREO

Company Profile

MREO logo image Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. The firm has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development, which include Etigilimab, an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity and Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late-line ovarian cancer.

Company Info

MEREO BIOPHARMA GROUP PL-ADR

One Cavendish Place, Fourth Floor

London W1G0QF GB

CEO: Denise Scots-Knight

Employees: 36

MREO Company Website

MREO Investor Relations

Phone: 443330237300

MEREO BIOPHARMA GROUP PL-ADR / MREO FAQ

What is the stock price of MEREO BIOPHARMA GROUP PL-ADR today?

The current stock price of MREO is 1.85 USD. The price increased by 6.32% in the last trading session.


What is the ticker symbol for MEREO BIOPHARMA GROUP PL-ADR stock?

The exchange symbol of MEREO BIOPHARMA GROUP PL-ADR is MREO and it is listed on the Nasdaq exchange.


On which exchange is MREO stock listed?

MREO stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for MEREO BIOPHARMA GROUP PL-ADR stock?

15 analysts have analysed MREO and the average price target is 7.14 USD. This implies a price increase of 285.95% is expected in the next year compared to the current price of 1.85. Check the MEREO BIOPHARMA GROUP PL-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is MEREO BIOPHARMA GROUP PL-ADR worth?

MEREO BIOPHARMA GROUP PL-ADR (MREO) has a market capitalization of 294.15M USD. This makes MREO a Micro Cap stock.


How many employees does MEREO BIOPHARMA GROUP PL-ADR have?

MEREO BIOPHARMA GROUP PL-ADR (MREO) currently has 36 employees.


What are the support and resistance levels for MEREO BIOPHARMA GROUP PL-ADR (MREO) stock?

MEREO BIOPHARMA GROUP PL-ADR (MREO) has a support level at 1.79 and a resistance level at 1.86. Check the full technical report for a detailed analysis of MREO support and resistance levels.


Should I buy MEREO BIOPHARMA GROUP PL-ADR (MREO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does MEREO BIOPHARMA GROUP PL-ADR (MREO) stock pay dividends?

MREO does not pay a dividend.


When does MEREO BIOPHARMA GROUP PL-ADR (MREO) report earnings?

MEREO BIOPHARMA GROUP PL-ADR (MREO) will report earnings on 2025-11-10.


What is the Price/Earnings (PE) ratio of MEREO BIOPHARMA GROUP PL-ADR (MREO)?

MEREO BIOPHARMA GROUP PL-ADR (MREO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.35).


What is the Short Interest ratio of MEREO BIOPHARMA GROUP PL-ADR (MREO) stock?

The outstanding short interest for MEREO BIOPHARMA GROUP PL-ADR (MREO) is 38.1% of its float. Check the ownership tab for more information on the MREO short interest.


MREO Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to MREO. When comparing the yearly performance of all stocks, MREO is a bad performer in the overall market: 96.45% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

MREO Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to MREO. While MREO has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MREO Financial Highlights

Over the last trailing twelve months MREO reported a non-GAAP Earnings per Share(EPS) of -0.35. The EPS decreased by -50% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -79.29%
ROE -91.67%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%0%
Sales Q2Q%N/A
EPS 1Y (TTM)-50%
Revenue 1Y (TTM)-100%

MREO Forecast & Estimates

15 analysts have analysed MREO and the average price target is 7.14 USD. This implies a price increase of 285.95% is expected in the next year compared to the current price of 1.85.


Analysts
Analysts88
Price Target7.14 (285.95%)
EPS Next Y-9.51%
Revenue Next YearN/A

MREO Ownership

Ownership
Inst Owners71.8%
Ins Owners0.86%
Short Float %38.1%
Short Ratio4.5